The iconic rise of Viagra has consistently remained a example of pharmaceutical success, yet its future within the broader industry now triggers questions about future returns . Copycat versions are undercutting exclusivity , leading to worries that investing in companies significantly dependent to Viagra's once-dominant standing could be a specula